PA
BCRX icon

Profund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Profund Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
134,034
-24,428
-15% -$221K 0.04% 284
2026
Q1 		$1.51M Buy
158,462
+16,477
+12% +$128K 0.06% 249
2025
Q4 		$1.11M Buy
141,985
+61,966
+77% +$448K 0.03% 328
2025
Q3 		$607K Buy
80,019
+16,308
+26% +$136K 0.02% 450
2025
Q2 		$571K Buy
63,711
+9,730
+18% +$90.6K 0.02% 431
2025
Q1 		$405K Buy
53,981
+6,231
+13% +$50.3K 0.02% 547
2024
Q4 		$359K Sell
47,750
-26,753
-36% -$203K 0.01% 678
2024
Q3 		$566K Sell
74,503
-12,312
-14% -$93.6K 0.02% 487
2024
Q2 		$537K Sell
86,815
-155,057
-64% -$856K 0.02% 478
2024
Q1 		$1.23M Buy
241,872
+86,483
+56% +$486K 0.05% 305
2023
Q4 		$931K Buy
155,389
+18,737
+14% +$109K 0.04% 340
2023
Q3 		$967K Sell
136,652
-40,240
-23% -$289K 0.05% 293
2023
Q2 		$1.25M Buy
176,892
+24,138
+16% +$194K 0.07% 268
2023
Q1 		$1.27M Buy
+152,754
New +$1.47M 0.08% 236

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Profund Advisors's BCRX Position: Q2 2026 in Review

Profund Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 15% in Q2 2026, selling an estimated $221K and leaving 134,034 shares worth $1.34M. The position accounts for 0.04% of the portfolio, ranked #284.

Profund Advisors first reported a position in BCRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.51M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Profund Advisors held 134,034 shares of BioCryst Pharmaceuticals worth $1.34M as of Q2 2026.
  • Profund Advisors sold 24,428 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $221K.
  • BioCryst Pharmaceuticals made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #284 holding.
  • Profund Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's BioCryst Pharmaceuticals position peaked at $1.51M in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.